In a report published Friday, Credit Suisse analyst Jason Kantor reiterated an Outperform rating on Kite Pharma KITE, and raised the price target from $34.00 to $71.00.
In the report, Credit Suisse noted, “The strong showing of CAR-T therapies at the recent ASH meeting and the recent successful IPO of competitor JUNO demonstrate the sustained investor and physician enthusiasm for new immune-based and personalized therapies. We believe KITE will benefit in 2015 from the initiation of multiple trials expected to serve as pivotal studies, and we think a lucrative ex-US partner is likely. We are increasing our target price to $71 from $34. Addition of an ex-US partnership and the recent equity offering increase our forward EPS estimates.”
Kite Pharma closed on Wednesday at $58.10.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in